Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskPositive

Arrowhead Pharmaceuticals, Inc.

arrowheadpharmaceuticals.com
Filed: Jan 6, 2026CIK: 0000879407Health Care
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Arrowhead Pharmaceuticals held its 2026 Annual Meeting of Stockholders on March 19, 2026, where shareholders elected seven directors, approved executive compensation, authorized an amended incentive plan, and ratified KPMG LLP as auditors. This routine governance event demonstrates strong shareholder engagement with 119.8 million shares represented.

Key Takeaways

Seven directors were elected to the Board of Directors, indicating stable corporate governance

Shareholders approved executive compensation in a non-binding advisory vote, showing alignment on pay practices

3 more takeaways

Filing Overview

Form Type8-K
Filing DateJan 6, 2026
Item5.02
CategoryExecutive Change
CIK0000879407
Accession #arwr-20260319
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
board change

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings